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Abstract	
Cognitive	dysfunction	in	depression	is	associated	with	poorer	clinical	outcomes	and	interference	with	
psychosocial	 functioning.	 However,	 most	 treatments	 for	 depression	 do	 not	 specifically	 target	
cognition.	Neurocognitive	deficits	such	as	memory	and	concentration	problems	tend	to	persist	after	
mood	symptoms	recover.	Improving	cognition	in	depression	requires	a	better	understanding	of	brain	
systems	 implicated	 in	depression.	A	comprehensive	approach	 is	warranted	 for	 refined	methods	of	
assessing	and	treating	cognitive	dysfunction	in	depression.	
	
Depression	is	a	major	cause	of	disability	worldwide.	It	is	estimated	to	be	second	largest	contributor	to	
disease	burden	by	2020	according	to	World	Health	Organisation	(World	Federation	of	Mental	Health,	
2012).	Depression	could	interfere	with	various	aspects	of	functioning	including	work,	quality	of	life,	or	
psychosocial	 functioning.	At	workplace,	 depression	 is	 one	of	 the	main	 causes	 of	 absenteeism	and	
presenteeism	(Druss	et	al.	2001).	Absenteeism	refers	to	direct	impact	of	depression	on	occupational	
functioning	where	people	cannot	attend	work	due	to	depressive	 illness.	Presenteeism	is	related	to	
decreased	 performance	 at	work	when	 people	 still	 attend	 to	work	 despite	 ongoing	 illness	 or	 they	
cannot	return	to	previous	performance	levels	after	recovery.	Cognitive	symptoms	were	suggested	to	
be	major	factor	contributing	to	functional	impairments	(McIntyre	et	al.	2013).		
	
Clinically,	cognitive	symptoms	are	commonly	endorsed	by	the	patients	both	during	episodes	and	as	
residual	 symptoms	 (Conradi	 et	 al.	 2011).	 Numerous	 studies	 reported	 poorer	 neuropsychological	
performance	in	tests	of	memory,	attention	and	executive	function	in	patients	with	depression	(Bora	
et	al.	2013).	Cognitive	dysfunction	in	depression	is	associated	with	poorer	psychosocial	functioning	
(Jaeger	 et	 al.	 2006),	 and	 higher	 rate	 of	 relapse	 (Majer	 et	 al.	 2004).	 Memory	 and	 concentration	
problems	in	depression	are	linked	to	unemployment	or	work	impairment	(Buist-Bouwman	et	al.	2004,	
Lam	et	al.	2012).	The	impact	of	cognitive	dysfunction	on	functioning	may	be	related	to	persistence	of	
cognitive	deficits	even	after	mood	symptoms	recover.	A	meta-analysis	of	studies	using	a	standardised	
test	battery	(CANTAB)	showed	that	the	magnitude	of	cognitive	deficits	during	episode	and	in	remission	
were	comparable	(Rock	et	al.	2013).	On	the	other	hand,	recurrent	nature	of	depressive	disorders	and	
accompanying	cognitive	dysfunction	could	contribute	to	further	disability	associated	with	depression.	
The	 “toxicity”	 of	 repeated	 episodes	 (Gorwood	 et	 al.	 2008)	 on	 cognition,	 also	 known	 as	 “scarring”	
(Kessing,	1998)	was	proposed	to	explain	persistence	of	cognitive	dysfunction.	According	to	this,	each	
episode	 leads	 to	 accumulation	 of	 vulnerability,	 hence	 leading	 to	 further	 decline	 in	 cognitive	
functioning	over	 the	 years.	 In	 later	 life,	memory	deficits	 seen	 in	depression	 could	be	 vulnerability	
factors	for	dementia	(Kessing	&	Andersen,	2004).	In	a	longitudinal	epidemiological	study	(Baltimore	
Longitudinal	Study	of	Aging),	elevated	depressive	symptoms	over	the	life	course	were	associated	with	
increased	risk	of	dementia	(Dotson	et	al.	2010).	
	
Despite	the	clear	impact	on	the	course	of	depression,	cognition	is	yet	to	be	accepted	as	a	treatment	
target	for	depression.	In	a	recent	survey,	more	than	90%	of	the	patients	with	a	history	of	depression	
reported	significant	 impact	of	cognitive	problems	 in	their	daily	 living	activities.	However,	only	50%	
have	 ever	 been	 asked	 about	 cognitive	 dysfunction	 by	 a	 healthcare	 professional	 (Clark	 Health	
Communications,	2015).	Most	currently	available	treatments	were	shown	to	be	effective	for	overall	
mood	 symptoms,	 whereas	 the	 effects	 on	 cognitive	 functions	 were	 rarely	 tested	 in	 double-blind	
placebo	 controlled	 trials.	 The	 scarcity	 of	 evidence	 on	medication	 effects	 on	 cognitive	 functions	 in	
depression	 makes	 it	 difficult	 to	 draw	 conclusions.	 A	 comprehensive	 review	 on	 previous	 studies	
highlighted	the	problems	with	existing	research.	Mainly,	assessment	methods	and	clinical	features	of	
study	populations	varied	markedly.	Most	of	the	studies	were	not	placebo	controlled,	and	focus	was	
heavily	on	depression	in	older	adults.		Overall,	conventional	antidepressants	have	very	limited,	if	any	
effects	at	all	on	cognition	in	depression	(Keefe	et		al.	2014).	In	a	recent	randomised	longitudinal	study,	
it	 was	 shown	 that	 8-week	 treatment	 with	 escitalopram,	 sertraline,	 or	 venlafaxine	 did	 not	 have	
significant	 effects	 on	 cognitive	 functions	 as	 measured	 by	 a	 comprehensive	 neuropsychological	
battery.	This	applied	to	patients	 in	the	same	sample	who	have	achieved	clinical	remission	with	the	
treatment	(Shilansky	et	al.	2016).	The	persistence	of	cognitive	dysfunction	even	after	mood	symptoms	
recover	has	been	well	documented	in	previous	studies	(Hasselbach	et	al.	2011)	which	suggested	that	
cognitive	 functions	were	not	 addressed	by	medication.	However,	 recently	 licensed	 antidepressant	
vortioxetine	stands	out	among	other	antidepressants	as	it	was	shown	to	improve	cognitive	functions.	
The	first	study	to	report	pro-cognitive	effects	of	vortioxetine	showed	 improvement	 in	digit	symbol	
test	performance	in	elderly	depressed	patients	(Katona	et	al.	2012).	Consistent	with	the	initial	findings,	
a	 large	 randomized	controlled	 trial	 showed	 that	 vortioxetine	 improved	cognitive	 functions	 in	non-
elderly	patients	with	depression	 (McIntyre	et	al.	2014).	Multiple	 regression	analyses	 revealed	 that	
there	was	a	direct	effect	on	cognition	independent	from	the	effects	on	mood.	It	should	be	noted	that	
effect	sizes	for	most	tests	except	digit	symbol	substitution	test	were	small	in	this	study	and	replication	
is	 needed.	 Vortioxetine	 is	 a	 multi-modal	 pharmacological	 agent	 acting	 on	 a	 number	 of	
neurotransmitters	 including	 dopamine,	 noradrenaline,	 and	 diverse	 actions	 on	 different	 serotonin	
receptors.	It	was	suggested	that	the	pro-cognitive	effect	of	vortioxetine	might	be	associated	with	its	
stimulatory	effects	if	5-HT1A	receptors	and	its	inhibitory	effects	on	5-HT3.	Both	mechanisms	enhance	
cortical	glutamatergic	transmission	(Mørk	et	al.	2012).	Another	noteworthy	medication	is	modafinil	
which	was	shown	to	improve	cognition	in	depression	as	adjunctive	treatment	(DeBattista	et	al.	2004).	
One	 of	 the	 proposed	 mechanisms	 of	 modafinil’s	 pro-cognitive	 effect	 is	 through	 augmenting	
glutamatergic	 transmission	 in	hippocampus	 (Scoriels	et	 al.	 2013).	Modafinil	 augmentation	 showed	
beneficial	 effects	 on	mood	 and	 fatigue	 (Goss	 &	 Kaser	 et	 al.	 2013)	which	may	make	 its	 use	more	
favourable	for	patients	with	persistent	cognitive	dysfunction.		
	
There	 is	 suggestion	 that	 monoaminergic	 antidepressants	 may	 have	 favourable	 effects	 on	 hot	
(emotion-laden)	cognition.	Antidepressants	were	shown	to	alter	response	biases	to	emotional	stimuli	
very	 early	 in	 the	 course	 of	 treatment	 (Harmer	 et	 al.	 2009).	 The	mechanism	 linking	 this	 effect	 to	
therapeutic	 effects	 is	 yet	 to	 be	 elucidated.	 The	 interplay	 between	 negative	 emotional	 biases	 and	
cognitive	 functions	 in	 depression	 has	 been	 formulated	 in	 cognitive	 neuropsychological	 model.	
According	to	this	model	proposed	by	Roiser,	Elliott	and	Sahakian	(Roiser	et	al.	2012,	Figure	1),	bottom-
up	affective	biases	and	top-down	attentional	biases	(due	to	dysfunctional	cognitive	control)	help	to	
maintain	 the	depressive	state.	Pharmacological	 interventions	 (i.e.	antidepressant	medication)	alter	
the	affective	processing	of	emotional	stimuli,	thus	helping	to	reverse	negative	biases	and	eventually	
leading	to	remission	of	mood	symptoms.	Within	this	model,	psychological	treatments	are	suggested	
to	work	towards	gaining	cognitive	control	over	negative	biases.	Cognitive	neuropsychological	model	
could	help	guiding	the	research	to	identify	treatments	specifically	addressing	cognition.		
	
The	challenges	and	potential	research	areas	into	cognitive	dysfunction	in	depression	were	published	
in	 a	 report	 by	 National	 Academy	 of	 Sciences	 (National	 Academies	 of	 Sciences,	 Engineering,	 and	
Medicine,	 2015).	 It	 is	 highlighted	 that	 one	 of	 the	 main	 points	 regarding	 research	 into	 new	
interventions	is	the	need	for	change	in	trial	designs	to	include	cognitive	outcomes.	Regulators	such	as	
Food	and	Drug	Administration	in	the	USA	hold	the	expectations	that	interventions	should	help	people	
to	function	better	in	work	and	daily	living	activities,	therefore	psychosocial	functioning	measures	are	
equally	 important.	 With	 the	 developing	 mobile	 technologies	 and	 more	 accessible	 neurocognitive	
testing	methods,	 future	studies	will	be	able	 to	provide	 the	much	needed	 information	on	cognitive	
functioning	in	depression.	New	trial	designs	could	be	utilised	to	test	the	promising	interventions	for	
improving	cognition	in	depression.			
	
In	summary,	cognitive	dysfunction	in	depression	is	a	significant	aspect	of	depression.	It	is	associated	
with	poorer	 functioning,	poses	 risk	 for	 relapse	and	persists	even	after	mood	symptoms	recover.	A	
more	comprehensive	and	refined	approach	 is	warranted	to	address	the	unmet	need	for	 improving	
cognitive	functions	in	depression.	In	our	opinion	cognition	is	a	key	target	for	treatment	in	depression.	
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